Esraa Menshawey

Esraa Menshawey

Auto-generated profile, based on publicly available information

Esraa Menshawey

Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ONOmnia Azmy Nabeh
Omnia Azmy Nabeh
LMLamiaa Mohammed Matter
Lamiaa Mohammed Matter
MKMahmoud Ahmed Khattab
Mahmoud Ahmed Khattab
EMEsraa Menshawey
Esraa Menshawey

1 September 2022 in Current Problems in Cardiology
Verified
Journal Article
Closed access
AAAntoine Fakhry AbdelMassih
Antoine Fakhry AbdelMassih
RMRahma Menshawey
Rahma Menshawey
EMEsraa Menshawey
Esraa Menshawey
AEAhmed Emad El-Maghraby
Ahmed Emad El-Maghraby
ASAhmed O. Sabry
Ahmed O. Sabry
HAHala Agha
Hala Agha


30 August 2021 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
ONOmnia Azmy Nabeh
Omnia Azmy Nabeh
MHMaiada Mohamed Helaly
Maiada Mohamed Helaly
RMRahma Menshawey
Rahma Menshawey
EMEsraa Menshawey
Esraa Menshawey
MNMohammed Mansoor Matooq Nasser
Mohammed Mansoor Matooq Nasser
AEAhmed Mohamed Diaa El-Deen
Ahmed Mohamed Diaa El-Deen
Arrhythmia, one of the most common complications of COVID-19, was reported in nearly one-third of diagnosed COVID-19 patients, with higher prevalence rate among ICU admitted patients. The underlying etiology for arrhythmia in these cases are mostly multifactorial as those patients may suffer from one or more of the following predisposing mechanisms; catecholamine surge, hypoxia, myocarditis, cytokine storm, QTc prolongation, electrolyte disturbance, and pro-arrhythmic drugs usage. Obviously, the risk for arrhythmia and the associated lethal outcome would rise dramatically among patients with preexisting cardiac disease such as myocardial ischemia, heart failure, cardiomyopathy, and hereditary arrhythmias. Considering all of these variables, the management strategy of COVID-19 patients should expand from managing a viral infection and related host immune response to include the prevention of predictable causes for arrhythmia. This may necessitate the need to investigate the role of some drugs that modulate the pathway of arrhythmia generation. Of these drugs, we discuss the potential role of adrenergic antagonists, trimetazidine, ranolazine, and the debatable angiotensin converting enzyme inhibitors drugs. We also recommend monitoring the level of: unbound free fatty acids, serum electrolytes, troponin, and QTc (even in the absence of apparent pro-arrhythmic drug use) as these may be the only indicators for patients at risk for arrhythmic complications.

1 July 2020 in Egyptian Pediatric Association Gazette
Verified
Journal Article
Open access
PDF file
AAAntoine Fakhry AbdelMassih
Antoine Fakhry AbdelMassih
AAAisha Said AbdelAzeam
Aisha Said AbdelAzeam
AAAya Ayad
Aya Ayad
AKAya Yasser Kamel
Aya Yasser Kamel
AKAyah Khalil
Ayah Khalil
SASalma Ali
Salma Ali
Background: Coronavirus disease 2019 (COVID-19) emerged as a small outbreak in Wuhan rapidly progressing into the deadliest pandemic since the Spanish flu of 1918. The disease was deemed trivial in children, until the reporting, few days ago, of an emerging pediatric multi-inflammatory syndrome mimicking Kawasaki disease (KD). Main body: This report reveals that coronaviridae were implicated in induction of several post-infectious vasculitides, namely, KD, AHEI, and HSP. This occurs in genetically susceptible individuals to vascular inflammation. Shared genetic susceptibilities between KD and CoV include genes encoding for CD 40, HLAB-15:03, and ACE. This leads to augmented inflammation with hypersecretion of cytokines especially IL-6. Conclusion: The revealed relationships between KD and CoV can help to predict the risk of KD in COVID-19 patients through screening levels of upregulated cytokines. It might also signify that classic treatment of KD with IVIG might need to be replaced with anti-cytokine therapy in COVID-19 patients.

1 August 2024 in JBJS Reviews
Verified
Journal Article
Closed access
ASAhmed O. Sabry
Ahmed O. Sabry
SHSherif Hassan
Sherif Hassan
RMRahma Menshawey
Rahma Menshawey
EMEsraa Menshawey
Esraa Menshawey
MHMariam Hegazy
Mariam Hegazy
MHMohamed Hegazy
Mohamed Hegazy
Background: Congenital femoral deficiency (CFD) presents a significant challenge in pediatric orthopaedics, characterized by a spectrum of congenital anomalies ranging from mild femoral shortening to complete absence of the proximal femur and hip joint. This review aims at reviewing the latest concepts of femoral limb lengthening modalities in treating CFD, to explore the efficacy, complications, and long-term outcomes of various surgical techniques. Methods: A comprehensive search of the literature was performed for clinical studies involving lengthening in patients with proximal focal femoral deficiency (PFFD) in several databases. Results: We analyze the evolution of limb lengthening procedures, from the Wagner and Ilizarov methods to the latest advancements in distraction osteogenesis, and assess their role in addressing the functional needs of patients. We also analyze the possible risk factors for the occurrence of complications with each method and alternatives to avoid them. Conclusion: The review highlights the importance of individualized treatment plans, considering factors such as the degree of femoral deficiency and the potential for achieving a functional limb length; however, it requires a multidisciplinary approach and careful preoperative planning to optimize patient outcomes. The review underlines the need for ongoing research to refine surgical techniques and to compare them and improve the quality of life for individuals with PFFD. Level of Evidence: Level III. See Instructions for Authors for a complete description of levels of evidence.